Articles
Data-backed commentary on market gaps, unsolved problems, and builder opportunities.
Why Your 14-Day Trial Is Costing You Money (And What 17,000 Apps Can Teach You About Fixing It)
We dug into one of the largest free trial datasets ever published. The headline: on annual plans, 30-day trials convert 86% better than short ones. But there's a catch for AI apps, and the education niche turns the whole model on its head. Here's what indie hackers and vibe coders need to know.
Superintelligence Hasn't Reached the ICU Yet — Why Healthcare Apps Still Matter
Pieter Levels argues that AI superintelligence is making all apps look the same and wiping out differentiation. But our data from 703 healthcare pain points tells a different story. In regulated, high-stakes environments, the real opportunity isn't slop — it's life-or-death problems that generic AI can't touch. PainSignal's severity scores point to massive gaps where builders can still create valuable, defensible solutions.
The Cotton Yoga Shorts Opportunity Isn't About Fertility
A viral blog post claims polyester yoga shorts cause infertility and urges someone to invent cotton ones. But our data shows the real opportunity is much bigger: affordable natural fiber activewear that solves skin irritation, breathability, and sustainability for a market already demanding it.